News

5 December 2022 – Meradan® is a steroid cream containing 0.1% mometasone furoate and physiological lipids including ceramide found in Ceradan® cream. This formula is developed with skin barrier repair properties in mind. This is important because steroid creams are known to cause skin thinning. Therefore, Meradan® confers an advantage over typical steroid creams that were formulated without skin barrier repair properties.

15 September 2022 – We are pleased to announce results of a clinical study on “The protective effect of a novel sunscreen against blue light”, published recently in the International Journal of Cosmetic Science, shows that TDF® Blu Voile Sunscreen provides 82% protection at the cellular level against the harmful effects of blue light irradiation.

14 Dec 2021 – We are pleased to announce that we have signed an exclusive license and supply agreement with Favorex Pte Ltd, a subsidiary of DKSH, to commercialise Ustekinumab biosimilar produced by Alvotech, in Singapore, Malaysia and the Philippines. Alvotech is a multinational biopharmaceutical company that focuses on the development and manufacturing of high quality biosimilars for global markets.

18 Jan 2021 – We have appointed JSPharma as an exclusive distributor of TDF Fairence® T-Complex in South Korea. JSPharma’s key customers include medical clinics, hospitals, and burn centres covering medical specialists such as dermatologists, plastic surgeons and aesthetic doctors. It currently represents several international brands from Europe and the United States.

12 Nov 2020 – We are delighted to welcome Shanghai Good Luck International Trading Co. Ltd. as an exclusive distributor of Ceradan®. Shanghai Good Luck has the integrated marketing capability and knowledge to sell and market professional products in the medical channel in all the major economic regions in Mainland China.

3 August 2020 – We have procured all rigths, titles and interests in the trademarks of CG 210 and CG4S from Legacy Healthcare (Switzerland) SA for Singapore and Malaysia, and will commence the sale and distribution of the CG 210 product series.

Update as of Feb 2022: In addition to UK patent, we have also received patents in the US, Singapore, and Malaysia.

13 July 2020 – Our patent for Ceradan® Advanced has been granted in the United Kingdom (UK) and is pending approval in 13 countries/region such as Singapore, Malaysia Vietnam, China, Europe, USA, etc.

17 Jun 2019 – Hyphens Pharma is the exclusive distributor for Syntellix AG products in Vietnam. Syntellix manufactures MAGNEZIX® for quicker and safer bone recovery.

30 May 2019 – We entered into exclusive distribution agreement for marketing and distribution of products specific to central nervous system for the Vietnam market. Lundbeck is a renowned global pharmaceutical company specialising in treatment of brain diseases.

21 March 2019 – The latest MoU will build on prior partnership and further enhance the relationship between both organisations in research and development activities for dermatologicals and cosmeceuticals targeting eczema, acne and pigmentary disorders.

18 November 2016 – Hyphens Pharma is currently licensing sugar-based surfactant micro-emulsions technology from A*STAR’s Institute of Chemical and Engineering Sciences (ICES). The license was resulted from a Research Collaboration Agreement (RCA) with A*STAR in earlier years.